Encorafenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer (label: metastatic NSCLC with a BRAF V600E mutation, with binimetinib), Melanoma, Metastatic Colorectal Cancer, Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (6)
US
  • BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC) • BRAFTOVI is indicated, in combination with cetuximab and fluorouracil-based chemotherapy , for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA- authorized test [see Dosage and Administration (2.1) ]. • BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA- authorized test, after prior therapy [see Dosage and Administration (2.1) ].
  • BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) BRAFTOVI is indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Product first approved 2018FDA label
EU
  • Braftovi in combination with Mektovi (binimetinib) for adults with advanced NSCLC with a BRAF V600E mutationkyodonewsprwire.jp
  • Braftovi in combination with cetuximab for adults with metastatic colorectal cancer with a BRAF V600E mutation after prior systemic therapy (EU supplemental approval, 2020)ono-pharma.com
  • Original EU marketing authorisation for Braftovi (melanoma indication first); MAH Pierre Fabre MedicamentEMA
Product first approved 2018
JP
  • Unresectable melanoma with a BRAF mutation, in combination with binimetinib (BRAFTOVI capsules)
Product first approved 2019ono-pharma.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Advanced Metastatic Colorectal Cancer
Melanoma
Other / comorbidity
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT03803553 · Massachusetts General Hospital
2020-04-16 – 2027-12 · Metastatic Colon Cancer, Stage III Colon Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05710406 · Alliance for Clinical Trials in Oncology
2023-08-16 – 2034-06-01 · Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
What this study did
Phase 2 (46)
Advanced Metastatic Colorectal Cancer
NCT05725200 · Oslo University Hospital
2022-09-27 – 2040-12-31 · Metastatic Colorectal Cancer
What this study did
NCT06411600 · Vall d'Hebron Institute of Oncology
2024-05-17 – 2029-05-01 · Metastatic Colorectal Cancer
What this study did
NCT05217446 · Pfizer
2022-07-11 – 2027-01-26 · Metastatic Colorectal Cancer
What this study did
NCT06640166 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2024-06-03 – 2026-06-30 · Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Colorectal Adenocarcinoma, Colorectal Cancer (CRC), Colorectal Cancer, Colon Cancer, Colon Adenocarcinoma, Colon Carcinoma, Colon Neoplasm
What this study did
NCT03693170 · Pierre Fabre Medicament
2019-01-17 – 2023-04-27 · BRAF V600E-mutant Metastatic Colorectal Cancer
What this study did
NCT01719380 · Pfizer
2012-11-23 – 2019-02-12 · Colorectal Cancer
What this study did
Colorectal Cancer
NCT07789210 · Zhejiang University
2026-06-30 – 2031-06-30 · Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib, Cetuximab N01
What this study did
NCT05706779 · Federation Francophone de Cancerologie Digestive
2023-02-13 – 2029-05-31 · Colorectal Cancer, BRAF V600E Mutation Positive
What this study did
NCT06207656 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2024-04-16 – 2029-04-01 · Colorectal Cancer
What this study did
NCT05308446 · National Cancer Institute (NCI)
2022-07-19 – 2027-06-01 · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT06578559 · Gruppo Oncologico del Nord-Ovest
2024-07-23 – 2026-10-20 · Colorectal Cancer
What this study did
NCT05576896 · Northwestern University
2022-10-10 – 2026-04-20 · Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
What this study did
NCT05510895 · AIO-Studien-gGmbH
2022-09-01 – 2025-01-31 · Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
What this study did
Melanoma
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
NCT05097378 · CCTU- Cancer Theme
2023-02-27 – 2028-05-31 · Melanoma, Cancer
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT02910700 · M.D. Anderson Cancer Center
2016-12-09 – 2027-12-08 · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04511013 · SWOG Cancer Research Network
2021-01-06 – 2027-06-30 · Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT04074096 · UNICANCER
2022-09-05 – 2027-03-27 · Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
What this study did
NCT05026983 · M.D. Anderson Cancer Center
2021-12-27 – 2027-02-02 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT03235245 · European Organisation for Research and Treatment of Cancer - EORTC
2018-10-30 – 2027-01 · Unresectable Stage III Melanoma, Stage IV Melanoma
What this study did
NCT05767879 · Leiden University Medical Center
2022-01-01 – 2026-01-01 · Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma
What this study did
NCT05304546 · Dr. Ronnie Shapira
2023-09-05 – 2025-07-17 · Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV
What this study did
NCT04221438 · ECOG-ACRIN Cancer Research Group
2021-09-22 – 2025-01-31 · Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
What this study did
NCT02631447 · Fondazione Melanoma Onlus
2016-11-14 – 2024-05-31 · Metastatic Melanoma
What this study did
NCT03898908 · Grupo Español Multidisciplinar de Melanoma
2019-07-18 – 2023-07-31 · Metastatic Melanoma, Brain Metastases
What this study did
NCT02159066 · Pfizer
2014-07-23 – 2023-01-10 · Melanoma
What this study did
NCT02263898 · Jonsson Comprehensive Cancer Center
2015-01 – 2020-12 · Recurrent Melanoma, Stage IV Melanoma
What this study did
NCT01894672 · Memorial Sloan Kettering Cancer Center
2013-07 – 2016-03-17 · Melanoma
What this study did
NCT01820364 · Array BioPharma
2013-11 – 2015-03 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT02109653 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2015-06 – 2017-11 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04324112 · National Cancer Institute (NCI)
2020-10-28 – 2029-06-30 · Hairy Cell Leukemia
What this study did
NCT04061980 · Providence Health & Services
2020-10-30 – 2028-12-30 · BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
What this study did
NCT03839342 · University Health Network, Toronto
2019-06-07 – 2026-12 · Solid Tumor
What this study did
NCT05097599 · Strata Oncology
2022-04-29 – 2024-06-12 · Cancer, Advanced Solid Tumor
What this study did
NCT04390243 · Academic and Community Cancer Research United
2020-11-16 – 2023-11-01 · Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03973918 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-07-29 – 2023-10-01 · High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
What this study did
NCT02834364 · University of Heidelberg Medical Center
2016-06 – 2023-03-29 · Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
What this study did
NCT01981187 · Pfizer
2014-01-14 – 2015-10-13 · Solid Tumor, Hematologic Malignancies
What this study did
Phase 1/2 (11)
Advanced Metastatic Colorectal Cancer
NCT04017650 · M.D. Anderson Cancer Center
2019-06-14 – 2027-12-30 · BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT05039177 · Erasca, Inc.
2021-09-20 – 2026-01-26 · Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT02278133 · Array BioPharma
2014-12 – 2017-06-23 · Metastatic Colorectal Cancer
What this study did
Melanoma
NCT06194929 · University of Utah
2024-03-20 – 2030-01-15 · Cutaneous Melanoma, Brain Metastases
What this study did
NCT04720768 · Peter MacCallum Cancer Centre, Australia
2020-06-04 – 2024-12-04 · Melanoma, Metastasis
What this study did
NCT02902042 · Prof. Dr. med. Dirk Schadendorf
2018-04-24 – 2020-11-30 · Malignant Melanoma
What this study did
NCT01777776 · Array BioPharma
2013-07 – 2015-04 · Locally Advanced Metastatic BRAF Mutant Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04585815 · Pfizer
2020-11-10 – 2024-10-29 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT03843775 · Memorial Sloan Kettering Cancer Center
2019-02-14 – 2023-09-02 · Advanced BRAF Mutant Cancers
What this study did
NCT01543698 · Pfizer
2012-05-28 – 2023-03-09 · Solid Tumors Harboring a BRAF V600 Mutation
What this study did
Phase 1 (17)
Advanced Metastatic Colorectal Cancer
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
NCT05743036 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
2023-02-27 – 2025-07-09 · Metastatic Colorectal Cancer
What this study did
NCT01436656 · Pfizer
2011-09-05 – 2022-11-07 · Melanoma and Metastatic Colorectal Cancer
What this study did
NCT04044430 · University of California, San Francisco
2020-08-31 – 2022-07-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
What this study did
Colorectal Cancer
NCT06102902 · National Cancer Institute (NCI)
2024-06-05 – 2027-01-30 · Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
What this study did
Melanoma
NCT04903119 · Rina Plattner
2022-06-01 – 2030-06-01 · Metastatic Melanoma, BRAF Gene Mutation
What this study did
NCT04741997 · H. Lee Moffitt Cancer Center and Research Institute
2021-05-24 – 2027-04 · Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
What this study did
NCT03543969 · H. Lee Moffitt Cancer Center and Research Institute
2018-06-14 – 2026-12 · Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
What this study did
NCT03864042 · Pfizer
2018-01-02 – 2023-05-29 · Advanced Solid Tumors, Metastatic Melanoma
What this study did
NCT04759846 · Pierre Fabre Medicament
2021-01-21 – 2023-05 · BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
What this study did
Non-Small Cell Lung Cancer
NCT02857270 · Eli Lilly and Company
2016-09-29 – 2022-10-24 · Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT05003622 · Pierre Fabre Medicament
2021-09-27 – 2022-05-06 · BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma
What this study did
Other / comorbidity
NCT04800822 · Pfizer
2021-03-17 – 2024-06-19 · Solid Tumor
What this study did
NCT05446142 · Pfizer
2022-07-01 – 2022-09-30 · Healthy
What this study did
Phase 4 (2)
Melanoma
Other / comorbidity
Early phase / not applicable (1)
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did

Competitive landscape

Other BRAF V600E drugs

HLX208. Compare all 2 BRAF V600E drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Encorafenib: this drugApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Encorafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2026-12 · NCT03839342 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-30 · NCT05706779 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-01-30 · NCT06102902 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-02-02 · NCT05026983 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2027-04 · NCT04741997 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-05-01 · NCT06411600 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT04017650 · CT.gov ↗
What to watch
Phase 2BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma …Active not recruiting
Est. primary completion 2027-12-30 · NCT04061980 · CT.gov ↗
What to watch
2028 (5)
January 2028 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-01-15 · NCT06194929 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-02 · NCT07178717 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-03-28 · NCT05985954 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-04-01 · NCT06207656 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT07789210 · CT.gov ↗
What to watch
2034 (1)
June 2034 (1)
Phase 2/3Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8 …Active not recruiting
Est. primary completion 2034-06-01 · NCT05710406 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch

See the full readout calendar ↗